Oligosecretary Myeloma: Prevalence and Its Clinical Significance
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02095379|
Recruitment Status : Completed
First Posted : March 24, 2014
Last Update Posted : March 24, 2014
|Condition or disease||Intervention/treatment|
|Multiple Myeloma||Other: oligosecretary|
Oligosecretary myeloma is a subgroup of multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day). Patients with oligosecretary myeloma do not have established methods for disease monitoring and clinical informations regarding oligosecretary myeloma are still largely unknown.
In this study, we aimed to investigate the prevalence and clinical course of oligosecretary myeloma.
|Study Type :||Observational|
|Actual Enrollment :||390 participants|
|Official Title:||Oligosecretary Myeloma: Prevalence and Its Clinical Significance|
|Study Start Date :||October 2013|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||February 2014|
Multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day)
- Number of patients with oligosecretary myeloma among multiple myeloma patients [ Time Frame: up to 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02095379
|Korea, Republic of|
|Samsung Medical Center|
|Seoul, Korea, Republic of|
|Principal Investigator:||Kihyun Kim||Samsung Medical Center|